NCT01796548

Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity

Extended-Release Oxybutynin in the Treatment of Neurogenic Detrusor Overactivity (RONDO)

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Janssen-Cilag Ltd.,Thailand · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effects and tolerability (how well a participant can stand a particular medicine or treatment) of flexible dose Oxybutynin Extended-Release (OXY-ER, Lyrinel) including safety and quality of life assessment in participants with neurogenic detrusor overactivity (NDO - the nerves mediating the detrusor muscle do not work properly leading to frequent feeling of need to urinate during the day, night, or both).

Detailed description

This is an open-label (all people know the identity of the intervention), single arm, prospective (study following participants forward in time), multi-center study of participants with NDO. The initial dose of Oxybutynin ER will be 10 milligram (mg) and will be titrated to a maximum of 30 mg. Dosage will be adjusted in 5-mg increments at approximately 14-day intervals until continence is achieved or the participant cannot tolerate side effects. The duration of participation in the study will be 12 weeks. The study will consist of 6 visits: baseline, Weeks 2, 4, 6, 8 and 12. Week 4 and Week 8 will be telephone visits. Overall safety and efficacy of Oxybutinin ER will be assessed as well as safety and efficacy during the titration and maintenance phases. The efficacy of treatment will be assessed using urodynamic parameters (the force and flow of urine) and clinical parameters (voiding diary and catheterization \[use or insertion of a tubular device to drain the bladder\] schedules). The quality of life will also be monitored in the study.

Conditions

• Detrusor Function, Overactive

Interventions

Type	Name	Description
DRUG	Oxybutinin Extended-Release	Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally

Timeline

• Start date: 2008-12-01
• Primary completion: 2010-12-01
• Completion: 2010-12-01
• First posted: 2013-02-21
• Last updated: 2013-11-26
• Results posted: 2013-07-31

Locations

3 sites across 1 country: Thailand